What Bioptimus does
Bioptimus develops foundation models — including H-Optimus for pathology and M-Optimus, which integrates pathology, spatial transcriptomics and genomics — that help pharmaceutical companies with drug discovery, biomarker identification and treatment-response prediction. The company says 16 of the top 20 pharmaceutical firms and more than 1,000 research institutions use its models, which have been downloaded over a million times. Bioptimus was founded in Paris in January 2023 by researchers from Google DeepMind, Owkin and Novartis. It raised a $41M Series A on January 14, 2025, led by Cathay Innovation, taking total funding to $76M, according to TechCrunch and Sofinnova Partners.
Bioptimus is a healthcare tool on Falcoscan. Builds multimodal AI foundation models for biology and drug discovery. Falcoscan rates Bioptimus with an Opportunity score of 84/100, a Saturation score of 11/100, and a Wrapper-risk score of 9/100. Market signal: rising. Bioptimus is founded in 2023, currently at Series_a stage. Pricing: Freemium.